您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Tamoxifen-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tamoxifen-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tamoxifen-d5图片
CAS NO:157698-32-3
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
他莫昔芬-d5 (ICI 47699-d5) 是氘标记的他莫昔芬。他莫昔芬 (ICI 47699) 是一种具有口服活性的选择性雌激素受体调节剂 (SERM)。 Tamoxifen 是一种有效的 Hsp90 激活剂,可增强 Hsp90 分子伴侣 ATPase 活性。
Cas No.157698-32-3
别名ICI 47699-?d5; (Z)-Tamoxifen-?d5; trans-Tamoxifen-?d5
Canonical SMILESCN(C)CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/C([2H])([2H])C([2H])([2H])[2H])C=C1
分子式C26H24D5NO
分子量376.6
溶解度DMF: 20 mg/ml,DMSO: 2 mg/ml,Ethanol: 20 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Tamoxifen-d5contains five deuterium atoms at the 3, 3, 4, 4, and 4 positions. It is intended for use as an internal standard for the quantification of tamoxifen by GC- or LC-MS. Tamoxifen is a selective estrogen receptor (ER) modulator, evoking tissue-dependent effects. It is an antagonist of ER action in breast tissue and breast cancer cells and is reported to be effective in the treatment of early breast cancer to prevent tumor growth.1,2Importantly, tamoxifen has been reported to act as an ER agonist in bone and blood vessels, helping to minimize osteoporosis and reduce the risk of cardiovascular disease in post-menopausal women.3Also, tamoxifen is a partial ER agonist in uterine tissues and is reported to increase the risk of endometrial carcinoma.4

1.Horwitz, K.B., and McGuire, W.L.Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processingJ. Biol. Chem253(22)8185-8191(1978) 2.Clarke, M., Collins, R., Davies, C., et al.Tamoxifen for early breast cancer: An overview of the randomised trialsLancet351(9114)1451-1467(1998) 3.Tonetti, D.A., and Jordan, V.C.Targeted anti-estrogens to treat and prevent diseases in womenMol. Med. Today2(5)218-223(1996) 4.Jordan, V.C., and Assikis, V.J.Endometrial carcinoma and tamoxifen: Clearing up a controversyClin. Cancer Res.1(5)467-472(1995)